Drug Developers and Marketers Re-tool their Strategies

As the Market for Hematopoietics Matures, Drug Developers and Marketers Re-tool their Strategies

Biosimilars and New NCEs Threaten Incumbent Products from Two Sides According to Greystone Research Associates

(Amherst, NH) – The market for drugs that are indicated for treating anemia and neutropenia has been dominated by biological drugs. After years of market stability, the current generation of branded therapeutics is coming under pressure from the first wave of biosimilars that are now reaching the market. Established suppliers - most notably market leader Amgen – are feeling the effects. We expect the revenue impact of lower cost EPO, G-CSF and GM-CSF biosimilars to result in a global market decrease of 51% on a revenue basis for this drug class by 2022.

The competitive landscape is further complicated by new classes of drugs with hematopoietic properties that are winding their way through the clinical trial process. These drugs are on course to begin entering the market by 2018. The challenges they will represent to sector participants, clinicians and managed care providers will introduce opportunities as well as risks to the market.

These market survey findings are detailed in a new and comprehensive report researched and written by Greystone Research Associates. Navigating the Maturing Market for Hematopoietics analyzes the global market for hematopoietics, providing assessments of demand drivers, development factors, market considerations, strategic and economic factors, and profiles of market sector participants.

ENDS

© Scoop Media